Besides, CITYSCAPE (44), a randomized, double-blind, placebo-controlled phase II clinical trial of anti-TIGIT antibody tiragolumab combined with atezolizumab in the first-line treatment of patients with PD-L1 positive non-small cell lung cancer, demonstrated that the objective response rate (ORR) of combination therapy was 31.3%. This evidence concerns the gene CD274 and non-small cell lung carcinoma.